![]() ![]() ![]() The randomized, placebo-controlled ADAURA trial enrolled 682 patients in early stages of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) following tumor resection and in some cases adjuvant chemotherapy. According to AstraZeneca, positive high-level results from the ADAURA trial showed Tagrisso demonstrated a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint, compared to placebo.ĪstraZeneca says the new data confirms Tagrisso's potential to extend patients’ lives in early-stage disease. ![]() AstraZeneca's EGFR inhibitor, Tagrisso, demonstrated strong overall survival benefit in a phase 3 trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer, according to the drugmaker. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |